Dimensional Fund Advisors LP Boosts Holdings in OptimizeRx Co. (NASDAQ:OPRX)

Dimensional Fund Advisors LP grew its holdings in shares of OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 9.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 444,167 shares of the company's stock after purchasing an additional 39,740 shares during the period. Dimensional Fund Advisors LP owned approximately 2.41% of OptimizeRx worth $2,159,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. SBI Securities Co. Ltd. acquired a new position in OptimizeRx in the fourth quarter valued at approximately $25,000. SG Americas Securities LLC bought a new position in OptimizeRx in the fourth quarter valued at approximately $51,000. Wells Fargo & Company MN increased its stake in OptimizeRx by 33.3% in the 4th quarter. Wells Fargo & Company MN now owns 11,208 shares of the company's stock valued at $54,000 after buying an additional 2,797 shares during the last quarter. Barclays PLC grew its position in shares of OptimizeRx by 358.5% in the 3rd quarter. Barclays PLC now owns 26,934 shares of the company's stock valued at $208,000 after acquiring an additional 21,060 shares during the period. Finally, XTX Topco Ltd bought a new stake in shares of OptimizeRx during the 4th quarter worth about $178,000. Hedge funds and other institutional investors own 76.47% of the company's stock.

Insiders Place Their Bets

In related news, Director James Paul Lang acquired 321,408 shares of the firm's stock in a transaction on Friday, March 14th. The stock was acquired at an average cost of $7.60 per share, for a total transaction of $2,442,700.80. Following the acquisition, the director now owns 389,452 shares of the company's stock, valued at $2,959,835.20. This trade represents a 472.35% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 5.60% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on OPRX. Citigroup reaffirmed an "outperform" rating on shares of OptimizeRx in a report on Tuesday, May 13th. B. Riley reissued a "buy" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Roth Capital reissued a "buy" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. JMP Securities raised their price target on shares of OptimizeRx from $11.00 to $14.00 and gave the company a "market outperform" rating in a research note on Tuesday, May 13th. Finally, Stifel Nicolaus raised their price target on shares of OptimizeRx from $8.00 to $12.50 and gave the stock a "buy" rating in a report on Tuesday, May 13th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $10.38.

OptimizeRx Price Performance

NASDAQ:OPRX traded up $0.79 during mid-day trading on Monday, hitting $12.22. 468,349 shares of the stock traded hands, compared to its average volume of 425,044. The business's 50-day moving average price is $8.74 and its 200 day moving average price is $6.49. The company has a market cap of $226.01 million, a PE ratio of -9.18 and a beta of 1.28. OptimizeRx Co. has a 12-month low of $3.78 and a 12-month high of $13.33. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported $0.08 EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.19. OptimizeRx had a negative net margin of 27.41% and a negative return on equity of 4.92%. The company had revenue of $21.93 million during the quarter, compared to analyst estimates of $18.69 million. On average, analysts expect that OptimizeRx Co. will post -0.33 EPS for the current fiscal year.

OptimizeRx Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.